scholarly journals Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes

2017 ◽  
Vol 83 (7) ◽  
pp. 1556-1570 ◽  
Author(s):  
Huang-Tz Ou ◽  
Kai-Cheng Chang ◽  
Chung-Yi Li ◽  
Jin-Shang Wu
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Antidiabetic Drugs ◽  
Cardiovascular Risks ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Third Line

scholarly journals Dipeptidyl Peptidase-4 Inhibitors as a Third-Line Oral Antihyperglycaemic Agent in Patients with Type 2 Diabetes Mellitus: The Impact of Ethnicity

2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
X. Zhang ◽  
B. Brooks ◽  
L. Molyneaux ◽  
E. Landy ◽  
R. Banatwalla ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Asian Patients ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Before And After ◽  
Third Line ◽  
And Gender ◽  
The Impact

Aims. The aim of this study is to examine the efficacy of adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with type 2 diabetes inadequately controlled by metformin and sulphonylurea combination treatment. The response of Asian and non-Asian patients to this regimen was also examined.Methods. The medical and computerized records of 80 patients were examined. These patients had baseline HbA1c levels ranging from 7.0 to 12.5% and had a DPP-4 inhibitor add-on therapy for a minimum period of 12 weeks. The primary endpoint was the change in HbA1c level before and after DPP-4 inhibitor treatment.Results. During oral triple therapy, there was a reduction of HbA1c from 8.3% (7.7–8.9) to 7.2% (6.8–7.6) and 26 patients (32.5%) achieved an HbA1c <7%. Poor baseline glycaemic control, lower BMI, and younger age were associated with a better response, but duration of diabetes and gender did not affect outcome. The HbA1c reduction was not different between Asians and non-Asians group [−1.00% (0.6–1.3) vs −0.90% (0.4–1.6)].Conclusions. DPP-4 inhibitor as a third-line add-on therapy can achieve significant glycaemic improvement in patients with type 2 diabetes inadequately controlled on the combination of metformin and sulphonylurea. The improvement in HbA1c was similar between Asian and non-Asian patients.

scholarly journals Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Cristiano S. Moura ◽  
Zale B. Rosenberg ◽  
Michal Abrahamowicz ◽  
Sasha Bernatsky ◽  
Hassan Behlouli ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Treatment Discontinuation ◽  
Nph Insulin ◽  
Dipeptidyl Peptidase 4 ◽  
Line Therapy ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Third Line Therapy ◽  
Third Line

Objective. To compare dipeptidyl peptidase-4 (DPP-4) inhibitors with neutral protamine Hagedorn (NPH) insulin, in terms of effectiveness and safety for the management of patients with type 2 diabetes mellitus (DM2) not controlled on metformin and sulfonylureas. Methods. A retrospective cohort study of individuals with DM2 newly dispensed with either DPP-4 inhibitors or NPH as third-line therapy, after metformin and sulfonylurea. Treatment discontinuation, macrovascular outcomes, and hypoglycemia were compared using multivariable Cox regression models, adjusted for sex, age, year of cohort entry, place of residence, hypertension, past history of hypoglycemia, diabetic ketoacidosis, comorbidities, and number of visits to emergency departments, outpatient physician, and hospitalizations. Results. Treatment discontinuation and hypoglycemia occurred more frequently with NPH than with DPP-4 inhibitor users. In the adjusted Cox model, the use of NPH compared to that of DPP-4 inhibitors was associated with a higher risk of discontinuation (HR: 1.33; 95% CI 1.27–1.40) and hypoglycemia (HR: 2.98; 95% CI 2.72–3.28). Risk of cardiovascular events was similar across groups. Conclusions. This real-world analysis suggests that DM2 patients initiating third-line therapy with NPH have poorer control of diabetes when compared to DPP-4 inhibitor initiators.

Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs

2011 ◽  
Vol 152 (37) ◽  
pp. 1471-1476 ◽  
Author(s):  
György Jermendy
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Antidiabetic Drugs ◽  
Dose Titration ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Dipeptidyl Peptidase 4 ◽  
Oral Antidiabetic ◽  
Dipeptidyl Peptidase 4 Inhibitors

Nearly 90% of the diabetic patients are suffering of type 2 diabetes while approximately 60-65% of patients with type 2 diabetes are treated with oral antidiabetic drugs. In the last couple of years a new treatment option, namely incretin-based therapy, became available. The dipeptidyl-peptidase-4-inhibitors (gliptins) are designated as incretin enhancers. Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. All gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin) can be used as tablets without a need for dose titration. For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin. Orv. Hetil., 2011, 152, 1471–1476.

Sign in / Sign up

Export Citation Format

Share Document